The Cell and Gene Therapy Catapult (CGT Catapult) announced that it will be...
Telstar Designs HVAC Control System to Provide Automatic Regulation in Cleanrooms
Telstar has announced that it has designed and developed a new heating, ventilation and air conditioning (HVAC) control system that has been proven to maintain an optimised quality of air through an automatic control mechanism.
C. Wayne Mcilwraith Translational Medicine Institute (TMI), Colorado State University (CSU)
Colorado State University (CSU) began construction of the C. Wayne McIlwraith Translational Medicine Institute (TMI) in June 2017.
Breaking cancer’s drug addiction
Cancer cells can become addicted to the drugs designed to kill them, and now a group of scientists from the Netherlands Cancer Institute has discovered the underlying mechanism. Abi Millar finds out why cells die en masse when treatment is removed and how this could be exploited in a clinical setting.
Merck to develop oncology drugs with Cancer Research UK and ICR
Merck has entered a multi-project collaboration and licensing deal with Cancer Research UK and the Institute of Cancer Research, London (ICR) for the discovery and development of new drugs to treat cancer.
Sanofi and Regeneron’s Kevzara faces competition in rheumatoid arthritis market
At the 36th annual J.P. Morgan Healthcare Conference, Sanofi and Regeneron discussed the anticipated success of Kevzara (sarilumab), an interleukin 6 (IL-6) inhibitor approved in 2017 for moderate to severely active rheumatoid arthritis (RA) patients with an inadequate response or intolerance to at least one disease-modifying anti-rheumatic drug (DMARD).
H&T Presspart to Attend Digitalization in Pharma Summit, Prague
H&T Presspart had announced it will be presenting its components for respiratory drug delivery systems at this year’s Digitalization in Pharma Summit.
Batavia Biosciences joins project to develop new polio vaccine
Biopharmaceutical manufacturer Batavia Biosciences is joining an international consortium to sustain a polio-free world once the disease has been eradicated.
FDA’s Mini-Sentinel finds no new concerns with Janssen’s Xarelto
A Mini-Sentinel assessment by the US Food and Drug Administration (FDA) has confirmed the positive safety and efficacy profile of Janssen Pharmaceutical’s Xarelto (rivaroxaban) determined in the Phase III ROCKET AF clinical trials.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.